My Treatment Approach: Advancing Treatment Strategies for HER2+ Metastatic Breast Cancer

Panelists discuss how trastuzumab deruxtecan (Enhertu) is used to treat HER2-positive metastatic breast cancer with brain metastases, emphasizing its effectiveness in achieving systemic tumor reduction and CNS lesion stabilization while exploring treatment challenges and emerging strategies in this patient population.

Panelists discuss how they approach the treatment of HER2-positive advanced breast cancer with brain metastases, outlining the criteria for therapy selection, the role of patient-specific factors in shaping treatment strategies, and situations where they might adjust their approach.

Panelists discuss the DESTINY-Breast12 trial, reviewing its study design, rationale, and key efficacy and safety findings in HER2-positive metastatic breast cancer patients with brain metastases, focusing on differences in outcomes between patients with active vs stable brain metastases, and the role of trastuzumab deruxtecan (T-DXd) in expanding treatment options for this patient population.